News

EMA Panel Recommends Approval of Biogen’s Spinraza in Europe

Spinraza (nusinersen), a treatment for most forms of spinal muscular atrophy (SMA), took a major step forward to becoming available across the European Union, with the Committee for Medicinal Products for Human Use (CHMP) recommending its approval. CHMP is a branch of the European Medicines Agency (EMA), the equivalent of…

Spinraza’s Benefits to Infants with Type 1 SMA Detailed at AAN Meeting

Motor milestones — a mark of life quality and potential longevity — are evident in a majority of infants with type 1 spinal muscular atrophy (SMA) treated with Spinraza (nusinersen) in a Phase 3 clinical trial, compared to those who received placebo. New interim trial data, in fact, found that 51 percent of Spinraza-treated infants continue…